21.08.2015 • News

Neste Jacobs Selected as FEED Contractor on Borouge Project

Finnish technology and engineering provider Neste Jacobs has been chosen by Borouge to provide front end engineering and design (FEED) services on a polyethylene plant modification in Ruwais, United Arab Emirates.

This is the third FEED project in a row that Neste Jacobs will deliver to Borouge under a long-term service (Tier 1) contract that the two companies signed previously. Neste Jacobs’ office in Abu Dhabi will carry out the work which will be completed this year.

“This contract is an important milestone in cooperation and partnership between Neste Jacobs and Borouge,” said Jarmo Suominen, CEO of Neste Jacobs. “This project is also proof that we are generating real added values for our customers and provide high quality services competitively in the Middle East and also globally.”

Abdulla N. Ateya, senior vice president of Borouge’s technical group, commented: “Neste Jacobs’ extensive know-how of our polyethylene process technology and our production plants combined with Neste Jacobs’ local presence in the Middle East were some of the most important selection criteria for choosing a FEED contractor.”

Meanwhile, Borouge’s new ethylene/polyethylene complex, Borouge 3, is nearing the final phase of commissioning. All five polymer plants have started operation with the remaining unit for cross-linked polyethylene due to go online by the end of this year. Once fully operational, Borouge’s total polyolefins capacity will reach 4.5 million t/y.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read